Introduction
Suppression of HIV replication and partial restoration of immune competence following administration of effective antiretroviral therapy has resulted in prolongation of survival of HIV-infected individuals. In addition, HIVassociated nephropathy (HIVAN) has diminished as a cause of renal dysfunction in areas of the world with adequate medical resources. Recipients of highly active antiretroviral therapy (HAART), however, are subject to diseases associated with aging such as diabetes, hypertension, and chronic kidney disease (CKD). Furthermore, specific antiretroviral agents are associated with diminished renal function.
Increasing renal disease in HIV-infected individuals
Adih et al. [1 ] have examined causes of death listed on death certificates of HIV-infected persons in the HAART era. Their analysis documented declines of death due to Acquired Immunodeficiency Syndrome (AIDS) in the USA. Non-AIDS deaths have in part replace AIDS as a cause of death, and renal disease was listed as the primary cause on 1682 of 13 750 (12.2%) of death certificates. A similar pattern of an increasing proportion of deaths due to non-AIDS conditions has been reported from Latin America [2] and by the D:A:D study [3] ; however, fewer deaths than reported by Adih were attributed to renal disease. A community-based investigation in Rakai, Uganda, noted that 8% of infected persons initiating HAART had mildly reduced estimated glomerular filtration (eGFR) or moderately reduced eGFR. This frequency of moderate reduction in eGFR was lower than that seen in HIV-infected African-Americans in Baltimore, Maryland, USA. The investigators speculated that the modification of diet in renal disease (MDRD) equation that they used to estimate GFR does not incorporate weight and would overestimate eGFR in lighter individuals who eat a diet lower in protein than that eaten by persons in industrialized countries where the MDRD was developed [4 ] .
Multiple publications have linked kidney function to morbidity and mortality [5 ] . Hemmelgarn et al. [6 ] reported that all-cause mortality, myocardial infarction, and progressive renal failure are increased in non-HIV infected in a community-based cohort study in Alberta,
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[8 ] also report data from a study of HIV-infected persons noting a 48% mortality in persons with eGFR of less than 60 and albuminuria and 23% mortality in those with eGFR of less than 60 alone and 20% mortality in those with albuminuria alone. Estrella et al.
[9 ] using data from the Women's Interagency HIV Study reported that kidney function at HAART initiation remained a determinant of mortality after adjusting for age, race, hepatitis C, AIDS, and CD4 þ T-cell count. Adjustment for hypertension and diabetes did not completely attenuate this risk. Specifically renal dysfunction as determined by eGFR and proteinuria were noted by George et al.
[10 ] to be associated with cardiovascular events in 63 patients compared with 252 matched controls without CVD in the Johns Hopkins HIV Clinic in the USA.
Measures of renal function
The critical issue of the method used to determine eGFR in the absence of a direct measure of GFR was discussed by Post et al. [11 ] . Serum creatinine-based estimates of GFR all have limitations. The Cockcroft-Gault equation adjusts for muscle mass and gender but not for tubular reabsorption of creatinine. The MDRD, also using serum creatinine, again does not account for tubular reabsorption of creatinine. Derived from both men and women the MDRD was compared with a direct measure of GFR, iothalamate clearance. The CKD Epidemiology Collaboration (CKD-EPI) also based upon serum creatinine combined data from more than 8000 persons in 10 different studies and was validated in an external sample. The CKD-EPI is more accurate than the Cockcroft-Gault or MDRD equations in persons with normal renal function. However, only small studies of renal function have been conducted in HIV-infected persons. Cystatin C has been proposed as an alternate to creatinine as it is not influenced by muscle mass and tubular secretion. Post et al. 
HIV-associated nephropathy
HIVAN is the most common cause of CKD in HIVinfected persons of African descent who are not receiving HAART. HIV mediates dysregulation of glomerular podocytes, the epithelial cells which maintain the glomerular basement membrane, and apoptosis of renal tubular cells. The resulting lesion of HIVAN is a focal glomerulosclerosis (FGS) and microcytic dilation of tubules [14 ,15 ].
It appears that HIVAN occurs in the setting of specific host genes and it has been widely accepted that the gene encoding a nonmyosin A heavy chain (MYH9) is associated with FGS, HIVAN, and end-stage kidney disease (ESKD) due to hypertension in persons of African descent [16, 17] . Recently, however, Genovese et al. [18 ,19 ] have reported that genome-wide association analysis in African-Americans and European-Americans with FGS identified a 60-kb region on chromosome 22 which contains MYH9 and a gene which transcribes a trypanolytic APOL1 variant protein which lyses Trypanosoma brucei. This variant was found in African-Americans but not in European-Americans and was presumably selected because of exposure to trypanosomes in Africa. Genovese et al. state that this 60-kb region spans disequilibrium blocks which includes the gene encoding MYH9. This and a later publication from this group noted that APOL1 variants are absent in Europeans. Other investigators have confirmed the association of the APOL1 variant and FGS in African-Americans [20 ].
The interaction of HIV with renal cells has not been clarified. Renal cells lack the classic receptors for HIV, CD4, and the chemokine receptors CCR5 and CXCR4.
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However, HIV-mRNA has been detected in renal epithelial cells, and HAART slows progression of HIVAN to renal failure [21 ] . Nonconventional receptors on renal cells such as C-type lectins including DC-Sign and lipid rafts have been suggested as portals of entry of HIV into renal cells [22 ] . Renal cell infection by HIV, however, is nonproductive [23] . Host factors such as activation of the renin-angiotensin-aldosterone system have also been implicated in the pathogenesis of HIVAN, and blocking production of Angiotensin II slows progression of HIVAN [15] . Finally, Sharma et al. [24] suggest that the NOTCH signaling pathway is activated by HIV proteins leading to cellular dysregulation of podocytes and dedifferentiation of these cells.
Of interest is a recent report that African American men with undetectable plasma HIV-RNA but high proviral DNA were at risk for HIVAN as documented by renal biopsy [25 ] .
Other infections and renal disease
The major co-infection associated with renal disease in the presence of HIV infection is hepatitis C virus (HCV). As reviewed by Operskalski and Kovacs [26 ] , patients with HIV/HCV demonstrate proteinuria, acute interstitial nephritis, and acute tubular necrosis, although the mechanism underlying the pathogenesis of these conditions is unknown. In contrast, membranoproliferative glomerulonephritis secondary to B-cell stimulation increased cryoglobulin production and deposition in the renal vasculature has been well documented. CKD in HIV/HCV-infected persons is associated with reduced survival as reported from a large study from the Veterans Administration [27 ] . Smaller studies have documented that co-infection increases the risk death as compared with HCV or HIV mono-infections [28] . Finally, in Cape Town, South Africa where tuberculosis is endemic, granulomatous tubercular interstitial nephritis has been recognized as a cause of proteinuric CKD in children [29] .
Antiretroviral drugs and renal disease
Several large investigations have reported that renal impairment is associated with administration receipt of tenofovir or indinavir [30 -33 ] . In the EuroSida study the incidence rate ratio of developing CKD for cumulative exposure to tenofovir was 1.16 [95% confidence interval (CI) 1.06-1.25], indinavir 1.12 (95% CI 1.06-1.18), atazanavir 1.12 (95% CI 1.09-1. 35 ), and lopinavir/ ritonavir 1.08 (95% CI 1.01-1.16) all significant increases [34 ] . Rodriguez-Novoa et al. [35] noted that although tenofovir has clinically unimportant effects upon eGFR, high plasma trough levels are associated with renal tubular dysfunction. Specific polymorphisms in genes coding transport proteins have been associated with tubular damage with tenofovir administration. Labarga et al. [36] have also reported tubular damage in patients with little or no loss of creatinine clearance. In multivariate analysis comparing 154 patients receiving tenofovir, 49 on other HAART regimens and 81 untreated HIV patients the odds ratios predicting tubular dysfunction was 21.6 (95% CI 4.1-113) [35] . Post et al.
[11 ] also noted that routine measurement of urinary biomarkers of tubular function in clinical practice is not indicated. Several reports in children have also emphasized the use of tenofovir in association with tubular dysfunction in the absence of changes in eGFR. Judd et al. [37] noted that tubular dysfunction is associated with prolonged use of the tenofovir and is generally reversible with withdrawal of the drug.
Raltegravir has been reported to be associated with rhabdomyolysis and renal dysfunction in three cases [38] . The fact that raltegravir has a low molecular weight and is highly soluble in water suggests that it would be removed by hemodialysis. In two patients with ESRD, however, hemodialysis minimally removed raltegravir [39] . The pharmacokinetics of the as yet unreleased CCR5 antagonist, vicriviroc, is not altered in patients with ESKD and the plasma concentration postdialysis was similar to predialysis levels [40] .
Treatment of renal disease in HIV-infected persons
Reducing the prevalence of renal disease in HIV-infected persons will have an impact upon non-AIDS morbidity and mortality. Szczech [21 ] has pointed out that although HAART slows progression of HIVAN, it is likely that the prevalence of CKD will increase with prolongation of survival and the probable increase of hypertension and diabetes in HAART-treated HIV persons. Furthermore, biopsy data is rare which prevents developing rationale treatment of other forms of renal disease. Arendse et al. have noted in Cape Town that acute tubular necrosis, nephrotoxic drug exposure, and hypovolemic shock were diagnosed in 58% of hospitalized HIV patients requiring renal support. Renal biopsies demonstrated HIVAN in 20%, and 10% had other renal pathology. HIVAN was most commonly seen in late stages of HIV infection, and it has not been established when institution of HAART is no longer effective in slowing or reversing HIVAN [41] . The experience in Cape Town illustrates also that immune complex nephritis alone or in combination with HIVAN was found in a large number by biopsy and that the treatment of immune complex nephritis has not been established.
Szczech et al. [42 ] noted that microalbuminuria predicts proteinuria in HIV-infected individuals and studies have linked proteinuria to CVD and mortality. The author suggests that treatment strategies such as angiotensin receptor blockers and HAART need to be evaluated to determine if management of microalbuminuria can prevent these outcomes.
Stock et al. [43 ] have reported the experience of a multicenter investigation of renal transplantation in HIV-infected persons with ESRD receiving HAART. Eligibility depended upon control of HIV infection and a CD4 þ T-cell count greater than 200 cells/ml. In persons with evidence of viral hepatitis a liver biopsy was obtained to rule out cirrhosis. Prophylaxis for opportunistic pathogens was utilized as clinically indicated. The recipients were followed for a median of 1.7 years. Both living and deceased donors were utilized. Survival at 1 and 3 years was 94.6 and 88.2% and graft survival was 90.4 and 73.7%, respectively. These results were equivalent to those seen in non-HIV-infected graft recipients older than 65 years of age. Few recipients showed progression of HIV infection; however, the cumulative incidence of rejection was 31% (95% CI 24-40) at 1 year and 41% (95% CI 32-52) at 3 years, which is higher than seen in non-HIV-infected graft recipients. The authors, in summary, state that renal transplantation is feasible in appropriately selected HIV-infected patients. Strategies to lower graft rejection are needed.
Other investigators have evaluated whether or not HIVinfected persons with ESRD would accept a kidney from an HIV-infected donor. A majority, under specific circumstances would consider acceptance of a graft from an infected donor [44] . A companion paper raised the issue of whether it was ethical to inform a living donor that the recipient was HIV infected. The authors concluded that the privacy of the recipient was paramount and that the donor should be told only that the potential recipient required a renal transplant [45] .
Conclusion
Renal disease represents an increasing cause of morbidity and mortality in HIV-infected individuals who are surviving longer due to effective antiretroviral therapy. Longitudinal studies of renal disease in HIV-infected persons receiving or not receiving HAART, however, are not yet available. Effective treatment when initiated early GFR in HIV-infected persons has not been clearly established. Clinically management of HIV infection includes monitoring of serum creatinine and urinary albumin or protein as well as treatment of hypertension and diabetes. Successful renal transplantation of selected HIV-infected persons represents a major breakthrough in the management of this condition.
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